Andere Sprachen Fractyl Health, Inc.

Aktien

A3EKLV

US35168W1036

GUTS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.05.2024			% 5 Tage	% 1. Jan.
7,46 ^USD	-1,32 %		+7,03 %	0,00 %

20.05.	Fractyl Health, Inc. präsentiert auf der Digestive Disease Week 2024 überzeugende präklinische Daten der GLP-1-Gentherapie für die Bauchspeicheldrüse Rejuva bei einmaliger Verabreichung	CI
13.05.	Fractyl Health, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024	20.05.
Fractyl Health, Inc. Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva At Digestive Disease Week 2024	20.05.
Earnings Flash (GUTS) FRACTYL HEALTH Reports Q1 Revenue $33,000	13.05.
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates	13.05.
Fractyl Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes	13.05.
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)	13.05.
Fractyl Health to Present at BofA Securities 2024 Health Care Conference	08.05.
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024	07.05.
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting	30.04.
Fractyl Health Names Adrian Kimber Chief Commercial Officer; Shares Down	02.04.
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes	02.04.
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes	02.04.
Fractyl Health, Inc. Announces Appointment of Adrian Kimber as Chief Commercial Officer	02.04.
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	01.04.
Rising Rate Cut Hopes Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Monday	01.04.
Top Premarket Decliners	01.04.
Fractyl Health Shares Drop After Wider 4Q Loss	01.04.
Earnings Flash (GUTS) FRACTYL HEALTH Posts Q4 Revenue $7,000	01.04.
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	01.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Fractyl Health, Inc.

Aktien

A3EKLV

US35168W1036

GUTS

Andere Sprachen

Filter